A monoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains

Biochimica et Biophysica Acta - General Subjects

Volumn 1770, Issue 2, 2007, Pages 178-186

  Martens, Erik ^a   Leyssen, An ^a   Van Aelst, Ilse ^a   Fiten, Pierre ^a   Piccard, Helene ^a   Hu, Jialiang ^a   Descamps, Francis J ^a   Van den Steen, Philippe E ^a   Proost, Paul ^a   Van Damme, Jo ^a   Liuzzi, Grazia Maria ^b   Riccio, Paolo ^c   Polverini, Eugenia ^d   Opdenakker, Ghislain ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY OF BARI   (Italy)

^c UNIVERSITY OF BASILICATA   (Italy)

^d UNIVERSITY OF PARMA   (Italy)

Author keywords

Domain mapping; Gelatinase B; Hydrophilicity; Matrix metalloproteinase 9; Monoclonal antibody

Indexed keywords

FIBRONECTIN; GELATINASE B; GELATINASE INHIBITOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY REGA 3G12; PROTEINASE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTIBODY COMBINING SITE; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CHEMICAL STRUCTURE; COMPETITIVE INHIBITION; CONFORMATION; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME DEGRADATION; ENZYME PURIFICATION; GLYCOSYLATION; HYDROPHILICITY; HYDROPHOBICITY; INSECT CELL; MOLECULAR INTERACTION; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; ZINC BINDING SITE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; BINDING SITES; CATALYTIC DOMAIN; CLONING, MOLECULAR; DNA, COMPLEMENTARY; ENZYME INHIBITORS; FIBRONECTINS; HUMANS; INSECTS; MATRIX METALLOPROTEINASE 9; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; VARIATION (GENETICS); ZINC;

INSECTA;

EID: 33845910687     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2006.10.012     Document Type: Article

References (37)

1. Van den Steen P.E., Dubois B., Nelissen I., Rudd P.M., Dwek R.A., and Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit. Rev. Biochem. Mol. Biol. 37 (2002) 375-536
2. Masure S., Proost P., Van Damme J., and Opdenakker G. Purification and identification of 91-kDa neutrophil gelatinase. Release by the activating peptide interleukin-8. Eur. J. Biochem. 198 (1991) 391-398
3. Opdenakker G., Van den Steen P.E., and Van Damme J. Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol. 22 (2001) 571-579
4. Hua J., and Muschel R.J. Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res. 56 (1996) 5279-5284
5. Egeblad M., and Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev., Cancer 2 (2002) 161-174
6. Coussens L.M., Fingleton B., and Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295 (2002) 2387-2392
7. Neuhaus O., Archelos J.J., and Hartung H.P. Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection. Trends Pharmacol. Sci. 24 (2003) 131-138
8. Christiansen J., and Rajasekaran A.K. Biological impediments to monoclonal antibody-based cancer immunotherapy. Mol. Cancer Ther. 3 (2004) 1493-1501
9. Taylor P.C. Antibody therapy for rheumatoid arthritis. Curr. Opin. Pharmacol. 3 (2003) 323-328
10. Paemen L., Martens E., Masure S., and Opdenakker G. Monoclonal antibodies specific for natural human neutrophil gelatinase B used for affinity purification, quantitation by two-site ELISA and inhibition of enzymatic activity. Eur. J. Biochem. 234 (1995) 759-765
11. Zhou N., Paemen L., Opdenakker G., and Froyen G. Cloning and expression in Escherichia coli of a human gelatinase B-inhibitory single-chain immunoglobulin variable fragment (scFv). FEBS Lett. 414 (1997) 562-566
12. Hu J., Van den Steen P.E., Houde M., Ilenchuk T.T., and Opdenakker G. Inhibitors of gelatinase B/matrix metalloproteinase-9 activity comparison of a peptidomimetic and polyhistidine with single-chain derivatives of a neutralizing monoclonal antibody. Biochem. Pharmacol. 67 (2004) 1001-1009
13. Pruijt J.F., Fibbe W.E., Laterveer L., Pieters R.A., Lindley I.J., Paemen L., Masure S., Willemze R., and Opdenakker G. Prevention of interleukin-8-induced mobilization of hematopoietic progenitor cells in rhesus monkeys by inhibitory antibodies against the metalloproteinase gelatinase B (MMP-9). Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 10863-10868
14. Shimanovich I., Mihai S., Oostingh G.J., Ilenchuk T.T., Brocker E.B., Opdenakker G., Zillikens D., and Sitaru C. Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid. J. Pathol. 204 (2004) 519-527
15. Wilhelm S.M., Collier I.E., Marmer B.L., Eisen A.Z., Grant G.A., and Goldberg G.I. SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J. Biol. Chem. 264 (1989) 17213-17221
16. Van den Steen P.E., Van Aelst I., Hvidberg V., Piccard H., Fiten P., Jacobsen C., Moestrup S.K., Fry S., Royle L., Wormald M.R., Wallis R., Rudd P.M., Dwek R.A., and Opdenakker G. The hemopexin and O-glycosylated domains tune gelatinase B/MMP-9 bioavailability via inhibition and binding to cargo receptors. J. Biol. Chem. 281 (2006) 18626-18637
17. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
18. Benson B.J., and Hanahan D.J. Structural studies on bovine prothrombin. Isolation and partial characterization of the Ca2+ binding and carbohydrate containing peptides of the N-terminus region. Biochemistry 14 (1975) 3265-3277
19. McKay D.M., Shaw C., Thim L., Johnston C.F., Halton D.W., Fairweather I., and Buchanan K.D. The complete primary structure of pancreatic polypeptide from the European common frog, Rana temporaria. Regul. Pept. 31 (1990) 187-197
20. Apffel A., Fischer S., Goldberg G., Goodley P.C., and Kuhlmann F.E. Enhanced sensitivity for peptide mapping with electrospray liquid chromatography-mass spectrometry in the presence of signal suppression due to trifluoroacetic acid-containing mobile phases. J. Chromatogr. A. 712 (1995) 177-190
21. Shapiro S.D., Fliszar C.J., Broekelmann T.J., Mecham R.P., Senior R.M., and Welgus H.G. Activation of the 92-kDa gelatinase by stromelysin and 4-aminophenylmercuric acetate. Differential processing and stabilization of the carboxyl-terminal domain by tissue inhibitor of metalloproteinases (TIMP). J. Biol. Chem. 270 (1995) 6351-6356
22. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
23. Fleminger G., Hadas E., Wolf T., and Solomon B. Oriented immobilization of periodate-oxidized monoclonal antibodies on amino and hydrazide derivatives of Eupergit C. Appl. Biochem. Biotechnol. 23 (1990) 123-137
24. Elkins P.A., Ho Y.S., Smith W.W., Janson C.A., D'Alessio K.J., McQueney M.S., Cummings M.D., and Romanic A.M. Structure of the C-terminally truncated human ProMMP9, a gelatin-binding matrix metalloproteinase. Acta Crystallogr., D Biol. Crystallogr. 58 Pt. 7 (2002) 1182-1192
25. Cha H., Kopetzki E., Huber R., Lanzendorfer M., and Brandstetter H. Structural basis of the adaptive molecular recognition by MMP9. J. Mol. Biol. 320 (2002) 1065-1079
26. Rowsell S., Hawtin P., Minshull C.A., Jepson H., Brockbank S.M., Barratt D.G., Slater A.M., McPheat W.L., Waterson D., Henney A.M., and Pauptit R.A. Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor. J. Mol. Biol. 319 (2002) 173-181
27. Kleifeld O., Van den Steen P.E., Frenkel A., Cheng F., Jiang H.L., Opdenakker G., and Sagi I. Structural characterization of the catalytic active site in the latent and active natural gelatinase B from human neutrophils. J. Biol. Chem. 275 (2000) 34335-34343
28. Humphrey W., Dalke A., and Schulten K. VMD: visual molecular dynamics. J. Mol. Graph. 14 (1996) 33-38
29. Mattu T.S., Royle L., Langridge J., Wormald M.R., Van den Steen P.E., Van Damme J., Opdenakker G., Harvey D.J., Dwek R.A., and Rudd P.M. O-glycan analysis of natural human neutrophil gelatinase B using a combination of normal phase-HPLC and online tandem mass spectrometry: implications for the domain organization of the enzyme. Biochemistry 39 (2000) 15695-15704
30. Stefanidakis M., Björklund M., Ihanus E., Gahmberg C.G., and Koivinen E. Identification of a negatively charged peptide motif within the catalytic domain of progelatinases that mediates binding to leukocyte β2 integrins. J. Biol. Chem. 278 (2003) 34674-34684
31. Hu J., Fiten P., Van den Steen P.E., Chaltin P., and Opdenakker G. Simulation of evolution-selected propeptide by high-throughput selection of a peptidomimetic inhibitor on a capillary DNA sequencer platform. Anal. Chem. 77 (2005) 2116-2224
32. Jani M., Tordai H., Trexler M., Banyai L., and Patthy L. Hydroxamate-based peptide inhibitors of matrix metalloprotease 2. Biochimie 87 (2005) 385-392
33. Murphy G., Knauper V., Lee M.H., Amour A., Worley J.R., Hutton M., Atkinson S., Rapti M., and Williamson R. Role of TIMPs (tissue inhibitors of metalloproteinases) in pericellular proteolysis: the specificity is in the detail. Biochem. Soc. Symp. 70 (2003) 65-80
34. Steffensen B., Xu X., Martin P.A., and Zardeneta G. Human fibronectin and MMP-2 collagen binding domains compete for collagen binding sites and modify cellular activation of MMP-2. Matrix Biol. 21 (2002) 399-414
35. Ikejiri M., Bernardo M.M., Bonfil R.D., Toth M., Chang M., Fridman R., and Mobashery S. Potent mechanism-based inhibitors for matrix metalloproteinases. J. Biol. Chem. 280 (2005) 33992-34002
36. Van den Steen P.E., Opdenakker G., Wormald M.R., Dwek R.A., and Rudd P.M. Matrix remodelling enzymes, the protease cascade and glycosylation. Biochim. Biophys. Acta 1528 (2001) 61-73
37. Kotra L.P., Zhang L., Fridman R., Orlando R., and Mobasherry S. N-glycosylation pattern of the zymogenic form of human matrix metalloproteinase-9. Bioorg. Chem. 30 (2002) 356-370